Availability of two draft Internet/Social media guidances
(1) “Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices” posted at: http://www.fda.gov/downloads /Drugs/GuidanceComplianceReg ulatoryInformation/Guidances/UCM401079.pdf
(2) “Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices” posted at: http://www.fda.gov/downloads/Drugs/GuidanceComplianc eRegulatoryInformation/Guidances/UCM401087.pdf
Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document, contact (CDER) Julie Chronis at 301-796-1200; (CBER) Office of Communication, Outreach and Development at 800-835-4709 or 240-402-7800; (CVM) Thomas Moskal at 240-276-9300; or (CDRH) Deborah Wolf at 301-796-5732. Guidance for Industry Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD, 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document, contact (CDER) Jean-Ah Kang at 301-796-1200; (CBER) Office of Communication, Outreach and Development at 800-835-4709 or 240-402-7800; (CVM) Dorothy McAdams at 240-453-6802; or (CDRH) Deborah Wolf at 301-796-5732.
Comments